PERJETA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug PERJETA contains one active pharmaceutical ingredient (API):

1	Pertuzumab UNII K16AIQ8CTM - PERTUZUMAB
	Pertuzumab is a recombinant humanised monoclonal antibody that specifically targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab inhibits ligand-initiated intracellular signalling through two major signal pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K). Inhibition of these signalling pathways can result in cell growth arrest and apoptosis, respectively.
	Read more about Pertuzumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PERJETA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FD02	Pertuzumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
Discover more medicines within L01FD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10267J, 10308M, 10333W, 10334X
BR	Câmara de Regulação do Mercado de Medicamentos	529213110025202
CA	Health Products and Food Branch	02405016
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	H3120113
EE	Ravimiamet	1609512
ES	Centro de información online de medicamentos de la AEMPS	113813001, 113813001IP
FI	Lääkealan turvallisuus- ja kehittämiskeskus	574423
FR	Base de données publique des médicaments	60912227
GB	Medicines & Healthcare Products Regulatory Agency	221354, 368194
HK	Department of Health Drug Office	62758
IL	מִשְׂרַד הַבְּרִיאוּת	7116
IT	Agenzia del Farmaco	042682017, 050953013
JP	医薬品医療機器総合機構	4291424A1020
LT	Valstybinė vaistų kontrolės tarnyba	1069701
NL	Z-Index G-Standaard, PRK	105422
NZ	Medicines and Medical Devices Safety Authority	15722
PL	Rejestru Produktów Leczniczych	100299600
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64394001
SG	Health Sciences Authority	14501P
TN	Direction de la Pharmacie et du Médicament	6993211H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699505762791
US	FDA, National Drug Code	50242-145